Protein biomarkers increasingly play a vital role in advancing health research, driving drug development, and improving clinical outcomes. The close connection between protein biomarkers and human ...

Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, owing in part to the often late stage at which it is diagnosed. Biomarker development for HCC aims to improve ...

Cancer immunotherapy has significantly changed the clinical management of multiple malignancies, yet substantial challenges remain in identifying which ...

Alzheimer’s disease is defined by a progressive accumulation of misfolded proteins and neuronal loss that often predates clinical symptoms by years. Biomarkers aim to detect pathological hallmarks ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

NEW YORK, April 17, 2026--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), today announced multiple scientific ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

A research team working at MedUni Vienna has demonstrated that a specific component of the immune system (PTX-3) remains at significantly higher levels in the blood of patients who have suffered from ...

Alzheimer's disease has a long preclinical phase in which neuropathological changes, such as amyloid β (Aβ) and tau pathology, accumulate over many years.1 This preclinical phase provides an ...

BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...